================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 20, 2004
MEDICIS PHARMACEUTICAL CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18443 52-1574808
(State or Other (Commission File Number) (IRS Employer
Jurisdiction of Incorporation) Identification No.)
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of Principal (Zip Code)
Executive Offices)
Registrant's telephone number, including area code: (602) 808-8800
N/A
------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure
On April 20, 2004, Medicis Pharmaceutical Corporation (the "Company")
issued a press release announcing that it had entered into an asset purchase
agreement, license agreement and securities purchase agreement with BioMarin
Pharmaceutical, Inc.
A copy of the Company's press release is attached hereto as Exhibit
99.1.
Item 7. Financial Statements and Exhibits
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
99.1 Copy of press release, dated April 20, 2004, issued by Medicis
Pharmaceutical Corporation
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)
Date: April 21, 2004 /s/ Mark A. Prygocki, Sr.
----------------------------------------
Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Copy of press release, dated April 20, 2004, issued by
Medicis Pharmaceutical Corporation